Safinamide | MAO-B inhibitor; Parkinson’s therapeutic
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $48.00 | ||
| 25 mg | $220.00 |
Safinamide (133865-89-1) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1 Displays anticonvulsant activity2 and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4 A novel therapeutic for Parkinson’s disease with multiple modes of action.5 Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6
References/Citations:
1) Strolin Benedetti et al. (1994), The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats; J. Pharm. Pharmacol., 46 814
2) Fariello et al. (1998), Preclinical evaluation of PNU-151774E as a novel anticonvulsant; J. Pharmacol. Exp. Ther. 285 397
3) Maj et al. (1998), PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat; Eur, J. Pharmacol., 59 27
4) Gardoni et al. (2018), Safinamide Modulates Striatal glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia; J. Pharmacol. Exp. Ther., 367 442
5) Caccia et al. (2006), Safinamide: from molecular targets to a new anti-Parkinson drug; Neurology, 67(7 Suppl. 2) S18
6) Schapira et al. (2013), Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease; Eur. J. Neurol., 20 271
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Safinamide (133865-89-1) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1 Displays anticonvulsant activity2 and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4 A novel therapeutic for Parkinson’s disease with multiple modes of action.5 Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6
References/Citations:
1) Strolin Benedetti et al. (1994), The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats; J. Pharm. Pharmacol., 46 814
2) Fariello et al. (1998), Preclinical evaluation of PNU-151774E as a novel anticonvulsant; J. Pharmacol. Exp. Ther. 285 397
3) Maj et al. (1998), PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat; Eur, J. Pharmacol., 59 27
4) Gardoni et al. (2018), Safinamide Modulates Striatal glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia; J. Pharmacol. Exp. Ther., 367 442
5) Caccia et al. (2006), Safinamide: from molecular targets to a new anti-Parkinson drug; Neurology, 67(7 Suppl. 2) S18
6) Schapira et al. (2013), Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease; Eur. J. Neurol., 20 271
Related products
-
SAHA | HDAC inhibitor
From $35.00CAS:149647-78-9Catalog Number:10-1067Activity:HDAC inhibitorAlternate Names:VorinostatChemical Name:Suberoylanilide-hydroxamic acidMolecular Weight:264.33Molecular Formula:C14H20N2O3Solubility:Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml).Physical Properties:White solidPurity:98%
NMR (Conforms)Storage Temperature:RTStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months.Shipping Code:RT -
Thalidomide | E3 UB ligase inhibitor
From $50.00CAS:50-35-1Catalog Number:10-1115Activity:E3 UB ligase inhibitorChemical Name:N-(2,6-Dioxo-3-piperidinyl)phthalimide, racemicMolecular Weight:258.25Molecular Formula:C13H10N2O4Solubility:Soluble in DMSO (up to 5 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.Shipping Code:RT -
Sivelestat sodium | Leukocyte elastase inhibitor
From $54.00CAS:201677-61-4Catalog Number:10-1102Activity:Leukocyte elastase inhibitorAlternate Names:ONO-5046Chemical Name:N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium hydrateMolecular Weight:528.51Molecular Formula:C20H21N2O7S·Na·4H2OSolubility:Soluble in DMSO (up to 20 mg/ml).Physical Properties:White solidPurity:98% by HPLCStorage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 monthsShipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
